FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200589986> ?p ?o ?g. }

• W4200589986 endingPage "439" @default.
• W4200589986 startingPage "426" @default.
• W4200589986 abstract "To evaluate the long-term safety and efficacy of add-on cannabidiol (CBD) in patients with seizures associated with tuberous sclerosis complex (TSC) in the open-label extension (OLE) of the randomized, placebo-controlled phase 3 trial GWPCARE6 (NCT02544763). Results of an interim (February 2019 data cut) analysis are reported.Patients who completed the randomized trial enrolled to receive CBD (Epidiolex® in the United States; Epidyolex® in the EU; 100 mg/mL oral solution). The initial target dose was 25 mg/kg/day, which, based on response and tolerability, could be decreased or increased up to 50 mg/kg/day. The primary end point was safety. Key secondary end points included percentage reduction in TSC-associated (countable focal and generalized) seizures, responder rates, and Subject/Caregiver Global Impression of Change (S/CGIC).Of 201 patients who completed the randomized phase, 199 (99%) entered the OLE. Mean age was 13 years (range, 1-57). At the time of analysis, 5% of patients had completed treatment, 20% had withdrawn, and 75% were ongoing. One-year retention rate was 79%. Median treatment time was 267 days (range, 18-910) at a 27 mg/kg/day mean modal dose. Most patients (92%) had an adverse event (AE). Most common AEs were diarrhea (42%), seizure (22%), and decreased appetite (20%). AEs led to permanent discontinuation in 6% of patients. There was one death that was deemed treatment unrelated by the investigator. Elevated liver transaminases occurred in 17 patients (9%) patients; 12 were taking valproate. Median percentage reductions in seizure frequency (12-week windows across 48 weeks) were 54%-68%. Seizure responder rates (≥50%, ≥75%, 100% reduction) were 53%-61%, 29%-45%, and 6%-11% across 12-week windows for 48 weeks. Improvement on the S/CGIC scale was reported by 87% of patients/caregivers at 26 weeks.In patients with TSC, long-term add-on CBD treatment was well tolerated and sustainably reduced seizures through 48 weeks, with most patients/caregivers reporting global improvement." @default.
• W4200589986 created "2021-12-31" @default.
• W4200589986 creator A5008258554 @default.
• W4200589986 creator A5008698867 @default.
• W4200589986 creator A5032129336 @default.
• W4200589986 creator A5053002960 @default.
• W4200589986 creator A5067443324 @default.
• W4200589986 creator A5071907476 @default.
• W4200589986 creator A5075255162 @default.
• W4200589986 creator A5075540991 @default.
• W4200589986 date "2021-12-27" @default.
• W4200589986 modified "2023-10-14" @default.
• W4200589986 title "Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial" @default.
• W4200589986 cites W1520014842 @default.
• W4200589986 cites W156748014 @default.
• W4200589986 cites W1886226115 @default.
• W4200589986 cites W1965633103 @default.
• W4200589986 cites W1978389910 @default.
• W4200589986 cites W2016888102 @default.
• W4200589986 cites W2028110405 @default.
• W4200589986 cites W2060806258 @default.
• W4200589986 cites W2063309568 @default.
• W4200589986 cites W2064937568 @default.
• W4200589986 cites W2090460203 @default.
• W4200589986 cites W2100428079 @default.
• W4200589986 cites W2126467306 @default.
• W4200589986 cites W2383259826 @default.
• W4200589986 cites W2470905933 @default.
• W4200589986 cites W2511912940 @default.
• W4200589986 cites W2528830630 @default.
• W4200589986 cites W2560747241 @default.
• W4200589986 cites W2569230786 @default.
• W4200589986 cites W2620218661 @default.
• W4200589986 cites W2762538576 @default.
• W4200589986 cites W2785059893 @default.
• W4200589986 cites W2791384105 @default.
• W4200589986 cites W2804921146 @default.
• W4200589986 cites W2808053580 @default.
• W4200589986 cites W2886999430 @default.
• W4200589986 cites W2890093841 @default.
• W4200589986 cites W2905603477 @default.
• W4200589986 cites W2914333425 @default.
• W4200589986 cites W2992736548 @default.
• W4200589986 cites W3009130471 @default.
• W4200589986 cites W3115167315 @default.
• W4200589986 cites W4200589986 @default.
• W4200589986 cites W4210953366 @default.
• W4200589986 cites W4212928705 @default.
• W4200589986 cites W4256397550 @default.
• W4200589986 doi "https://doi.org/10.1111/epi.17150" @default.
• W4200589986 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34957550" @default.
• W4200589986 hasPublicationYear "2021" @default.
• W4200589986 type Work @default.
• W4200589986 citedByCount "27" @default.
• W4200589986 countsByYear W42005899862021 @default.
• W4200589986 countsByYear W42005899862022 @default.
• W4200589986 countsByYear W42005899862023 @default.
• W4200589986 crossrefType "journal-article" @default.
• W4200589986 hasAuthorship W4200589986A5008258554 @default.
• W4200589986 hasAuthorship W4200589986A5008698867 @default.
• W4200589986 hasAuthorship W4200589986A5032129336 @default.
• W4200589986 hasAuthorship W4200589986A5053002960 @default.
• W4200589986 hasAuthorship W4200589986A5067443324 @default.
• W4200589986 hasAuthorship W4200589986A5071907476 @default.
• W4200589986 hasAuthorship W4200589986A5075255162 @default.
• W4200589986 hasAuthorship W4200589986A5075540991 @default.
• W4200589986 hasBestOaLocation W42005899862 @default.
• W4200589986 hasConcept C118552586 @default.
• W4200589986 hasConcept C126322002 @default.
• W4200589986 hasConcept C142724271 @default.
• W4200589986 hasConcept C168563851 @default.
• W4200589986 hasConcept C187212893 @default.
• W4200589986 hasConcept C197934379 @default.
• W4200589986 hasConcept C202953159 @default.
• W4200589986 hasConcept C203092338 @default.
• W4200589986 hasConcept C204787440 @default.
• W4200589986 hasConcept C27081682 @default.
• W4200589986 hasConcept C2778186239 @default.
• W4200589986 hasConcept C2778375690 @default.
• W4200589986 hasConcept C2778715236 @default.
• W4200589986 hasConcept C2778980267 @default.
• W4200589986 hasConcept C2780580376 @default.
• W4200589986 hasConcept C71924100 @default.
• W4200589986 hasConceptScore W4200589986C118552586 @default.
• W4200589986 hasConceptScore W4200589986C126322002 @default.
• W4200589986 hasConceptScore W4200589986C142724271 @default.
• W4200589986 hasConceptScore W4200589986C168563851 @default.
• W4200589986 hasConceptScore W4200589986C187212893 @default.
• W4200589986 hasConceptScore W4200589986C197934379 @default.
• W4200589986 hasConceptScore W4200589986C202953159 @default.
• W4200589986 hasConceptScore W4200589986C203092338 @default.
• W4200589986 hasConceptScore W4200589986C204787440 @default.
• W4200589986 hasConceptScore W4200589986C27081682 @default.
• W4200589986 hasConceptScore W4200589986C2778186239 @default.
• W4200589986 hasConceptScore W4200589986C2778375690 @default.
• W4200589986 hasConceptScore W4200589986C2778715236 @default.
• W4200589986 hasConceptScore W4200589986C2778980267 @default.
• W4200589986 hasConceptScore W4200589986C2780580376 @default.

• next